MiR-100 overexpression attenuates high fat diet induced weight gain, liver steatosis, hypertriglyceridemia and development of metabolic syndrome in mice

Christian Smolka1, Delia Schlösser1, Catherine Hohnloser1, Xavier Bemtgen1, Caterina Jänich1, Laura Schneider1, Julien Martin1, Dietmar Pfeifer2, Martin Moser1, Peter Hasselblatt3, Christoph Bode1, Sebastian Grundmann1 and Franziska Pankratz1*

Abstract

Background: Diet-induced obesity can result in the development of a diverse spectrum of cardiovascular and metabolic diseases, including type 2 diabetes, dyslipidemia, non-alcoholic liver steatosis and atherosclerotic disease. MicroRNAs have been described to be important regulators of metabolism and disease development.

Methods: In the current study, we investigated the effects of ubiquitous miR-100 overexpression on weight gain and the metabolic phenotype in a newly generated transgenic mouse strain under normal chow and high fat diet and used microarray expression analysis to identify new potential target genes of miR-100.

Results: While transgenic overexpression of miR-100 did not significantly affect weight and metabolism under a normal diet, miR-100 overexpressing mice showed a reduced weight gain under a high fat diet compared to wildtype mice, despite an equal calorie intake. This was accompanied by less visceral and subcutaneous fat development and lower serum LDL cholesterol. In addition, transgenic miR-100 mice were more glucose tolerant and insulin sensitive and demonstrated increased energy expenditure under high fat diet feeding. A comprehensive gene expression profiling revealed the differential expression of several genes involved in lipid storage- and metabolism, among them CD36 and Cyp4A14. Our data showed a direct regulation of CD36 by miR-100, leading to a reduced fatty acid uptake in primary hepatocytes overexpressing miR-100 and the downregulation of several downstream mediators of lipid metabolism such as ACC1, FABP4, FAS and PPARγ in the liver.

Conclusions: Our findings demonstrate a protective role of miR-100 in high fat diet induced metabolic syndrome and liver steatosis, partially mediated by the direct repression of CD36 and attenuation of hepatic lipid storage, implicating miR-100 as a possible therapeutic target in liver steatosis.

Keywords: miR-100, CD36, Fatty acid uptake, Liver steatosis, Metabolic syndrome

Background

Metabolism defines the entirety of finely regulated biochemical processes which convert fuel from food into energy to facilitate the organism’s growth, survival and development. To maintain this energetic balance, cells have to be constantly provided with energy and substrates...
necessary to synthesize nucleic acids, carbohydrates, proteins and lipids. This is enabled by a complex orchestra of metabolic pathways as well as nutrient sensors in tissues and organs. Hyperalimentation can misbalance this metabolic equilibrium, resulting in obesity, dyslipidemia and insulin resistance and a severely increased risk for secondary cardiovascular and hepatic diseases (Almeida et al. 2021; Kiran et al. 2021; Mikusova et al. 2021; Riveragonzalez et al. 2021; Singh et al. 2021; Vural Keskinler et al. 2021; Yao et al. 2021). MicroRNAs (miRNAs) are short, non-coding RNAs which mostly regulate gene expression by interaction with the 3′UTR of their target mRNAs. MiRNAs play a pivotal role as fine tuners of metabolic processes in mammals (Rottiers and Naar 2012) and several “metabomiRs” have been shown to regulate cholesterol and fatty acid metabolism as well as to influence non-alcoholic liver steatosis and insulin resistance (Gerin et al. 2010; Horie et al. 2010; Li et al. 2020; Marquart et al. 2010; Najafishoushtari et al. 2010), thereby adding a new complexity to the metabolic network.

Additionally, many miRNAs have been shown to be differentially regulated in white adipose tissue of obese patients compared to non-obese individuals (Arner and Kulyte 2015; Martinelli et al. 2010; Ortega et al. 2010). Heneghan et al. showed that the expression of miR-17-5p and miR-132 differed significantly between obese and non-obese omental fat and the expression of these two miRNAs in blood and omental fat significantly correlated with leptin, body mass index (BMI) and fasting blood glucose (Heneghan et al. 2011). Keller et al. found an increased expression of miR-21 in human obesity accompanied with a positive correlation of BMI. Many other studies suggest a modification of miRNA expression in mouse models of obesity (Iacomino and Siani 2017), e.g. miR-342-3p, miR-142-3p, miR-142-5p, miR-21 and miR-379 have shown to be upregulated and miR-122, miR-133b and miR-1 to be downregulated during the development of obesity in mice (Chartoumpekis et al. 2012). These findings highlight the role of miRNAs in the field of obesity and related diseases, suggesting the modulation of miRNA expression as potential therapeutic strategy in diseases related to metabolic syndrome.

Our own group recently, identified a protective role of miR-100 in chronic vascular inflammation by direct suppression of mTOR, finally resulting in reduced expression of endothelial adhesion molecules. Surprisingly, we also found enhanced serum triglyceride and cholesterol level under pharmacological inhibition of miR-100 in mice fed with high fat diet (HFD), indicating an influence of this miRNA on metabolic processes (Pankratz et al. 2018).

Here, we describe an exclusive transgenic mouse strain globally overexpressing miR-100. Starting with a comprehensive gene expression profile in liver tissue we identified two genes downregulated by miR-100 namely Cyp4a14 and CD36, which are known to be involved in lipid metabolism and storage. Although we observed no changes neither in the genotype nor phenotype of our transgenic mice under normal diet, adding the metabolic stressor HFD revealed an altered lipogenic gene profile and fat composition in miR-100 overexpressing mice, overall pointing to a beneficial effect of miR-100 in HFD induced liver steatosis.

Material and methods

Animals

For all experiments, only male mice were used to minimize data variation which might occur due to the estrous cycle of female animals. C57BL/6j animals were purchased from Charles River or from local stock of the animal facility at the University Hospital Freiburg, Germany. The ubiquitous miR-100 overexpressing mice were obtained by breeding our transgenic BLU.miR-100loxP mice with the CMV-Cre deleter strain (B6.C-Tg(CMV-cre)1Cgn/j, The Jackson Laboratory). All mice were kept under a 12 h/12 h light/dark cycle in a specific pathogen-free animal facility with normal chow diet (ND) and water available ad libitum. For the induction of metabolic stress, resulting in obesity, mice were fed a high fat diet (HFD) (ssniff EF acc.D12492 (I) mod.) for 16 weeks ad libitum, beginning with 2–3 weeks of age. Experimental animal protocols were approved (number of approval: G-14/067) by the Regierungspraesidium Freiburg, Germany, and all studies conformed to the Guide for the Care and Use of Laboratory Animals published by the directive 2010/63/EU of the European Parliament. The composition of the used diets is listed in Additional file 1: Table S1 and S2.

Metabolic caging

Physiological parameter and metabolic rate of mice was measured in open circuit oxymax chambers, that are a part of the Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments, OH). All mice were housed in single cages under a 12 h/12 h light/dark cycle at ~23 °C, with food corresponding to the experimental group (either normal chow diet or HFD) and water ad libitum. Prior each setup, mice were weighed. Data from the monitoring cages were automatically collected for 48 h. To obtain reliable results we adapted our experimental conditions to the natural day/night cycle of the mice. As mice were set into the metabolic cages in the morning, we allowed them to acclimate for 24 h in the metabolic cages and used only data from the second day and night.
For indirect calorimetry, O₂ and CO₂ concentration of the air entering the chamber was compared to the air leaving the chamber. The sensors for O₂ and CO₂ were calibrated using a gas mixture with defined quantities of O₂, CO₂ and N₂. Ambulatory moving of the mice was measured with infrared beams around the cages.

Glucose and insulin tolerance test
Glucose (GTT) and insulin (ITT) tolerance tests were performed before and at the end of the HFD feeding period. For the GTT, all mice of the experimental groups were fasted over night for 12 h and injected intraperitoneally with a 20% glucose solution (2 g/kg). Blood from tail was collected before and after injection (at 15, 30, 60 and 120 min) and glucose was measured using an ACCU-CHEK Aviva glucometer (Roche Diagnostics). For the ITT, all mice of the experimental groups were fasted for 6 h over day and insulin (I1882, Merck) was injected intraperitoneally (0.75 U/kg). Blood was collected and glucose measured as done for the GTT.

Measurement of serum and liver cholesterol and triglycerides
Serum samples were taken under non-fasting conditions in the morning at the day of harvest following either high fat or normal chow diet. Serum cholesterol and triglycerides were measured according to the manufacturer’s instructions using the Cholesterol FS (cat. # 113009910021) and Triglyceride FS kit (cat. # 157609910021) from DiaSys, Holzheim, Germany. Briefly, 2 µl of serum sample was mixed with 200 µl of either kit reagent and incubated for 10 min at room temperature. Then, the change in color was measured in an ELISA reader (SpectraMax M2, Molecular Devices, Munich, Germany) at 500 nm against the blank and a standard. Liver cholesterol and triglycerides were determined by incubation of 200 µg total liver protein in 20 µl 0.9% NaCl with 30 µl isopropanol for 10 min at 37 °C with shaking. Afterwards, cell debris was pelleted by centrifugation at 12,000 × g for 10 min at 4 °C and supernatant was transferred to a new tube following complete evaporation of the liquid at 37 °C, with subsequent measurement using the Cholesterol FS and Triglyceride FS kits as described above.

Cell culture experiments
Primary hepatocytes were isolated from livers of C57BL/6 or ubiquitous miR-100 overexpressing mice. In brief, 8–10 weeks old wild type (n = 7) or miR-100 mice (n = 6) were anesthetized with thiopental (100 µg/g) and a catheter was placed into the inferior vena cava. After perfusion with heparin (100 U/100 g), a catheter was placed into the vena portae hepatis and all blood was washed out with perfusion medium I (Hanks buffer with 20 mM HEPES, 2 mM EGTA, 0.1% glucose). The dissociation of hepatocytes was achieved by perfusion with collagenase I (100 U/ml) containing medium (Hanks buffer with 20 mM HEPES, 5 mM CaCl₂) for 10 min. Perfused livers were passed through a 100 µm screening filter and collected by centrifugation at 50 × g for 2 min. Hepatocytes were re-suspended in Williams Medium E supplemented with 10% FCS, 100 nM dexamethasone, 1 µM insulin and 2 mM glutamine and plated at the desired number in collagen-coated cell culture dishes. After 5–6 h the medium was changed to the medium mentioned above without insulin.

Oil Red O staining
For Oil Red O staining, cryo preserved liver sections (8 µm) were air dried for 10 min and fixed in 4% formalin for 10 min. After washing for 5 min with tap water, slides were rinsed with 100% propylene glycol for 2 min and stained in Oil Red O solution (0.5% Oil Red O in 100% propylene glycol) for 25 min at 60 °C. After that, slides were rinsed with tap water for 5 min, washed with ddH₂O for 1 min and stained with hematoxylin (#1.05175.0500, modified acc. to Gill II, Merck, Darmstadt, Germany) for 90 s. Then, slides were rinsed in tap water for 2–5 min and mounted with aqueous mounting solution.

Fatty acid uptake assay
The uptake of fatty acids was measured by incubation of primary hepatocytes with 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (BODIPY FL C16) from Invitrogen. Isolated primary hepatocytes from WT and miR-100 overexpressing mice were cultured on collagen coated glass coverslips in a 12-well tissue culture chamber in Williams Medium E supplemented with 10% FCS, 100 nM dexamethasone and 2 mM glutamine for 24 h. After serum starvation for 3 h, cells were rinsed with 1 × PBS and subsequently incubated for 1 h with 1 × PBS supplemented with DMSO control or BODIPY FL C16 at a final concentration of 200 nmol/L. Afterwards, cells were rinsed three times with ice-cold 1 × PBS and fixed in 4% paraformaldehyde for 10 min. Then, pictures were made from random areas on the coverslip and all well-defined cells were contoured manually using the NIH ImageJ software and the fluorescence intensity was measured. The fluorescence was referenced to blank areas in the field of view and the DMSO control samples.
No obvious phenotypic changes in miR-100 overexpressing mice under normal chow diet (ND). a The schematic illustration of our miR-100 breeding strategy is shown. b The applied breeding scheme resulted in a ~22 fold overexpression of miR-100 in liver tissue of transgenic mice as identified using stem-loop based realtime PCR. c, d CD36 and Cyp4a14 were significantly downregulated in liver tissue of transgenic miR-100 mice compared to WT control as analyzed using quantitative real-time PCR analysis. e, f The gain in weight was similar in miR-100 mice compared to WT animals under normal chow diet. g The food intake in ND was comparable in WT and miR-100 mice. h, i No significant changes in serum aspartate (AST) and alanine (ALT) transaminases. (n = 5–6 for all experiments) Data represent mean values with SEM. n.s. not significant, *P < 0.05 and ***P < 0.001 vs. the corresponding control.
Luciferase reporter plasmid activity assay

The luciferase activity assay was done in a modified form as described before (Pankratz et al. 2018) using the Luc-Pair™ Duo-Luciferase Assay Kit 2.0 and the CD36 miTarget™ miRNA 3′ UTR target clone from GeneCopoeia according to the manufacturer protocol. Briefly, Huh7 cells were seeded at a density of $1 \times 10^4$ cells per well in a white 96 well plate with clear bottom at the day before the transfection. The next day, the cells were transfected with 50 ng of the CD36 3′ UTR reporter plasmid together with the miR-100 precursor molecule (premiR-100) or the miR-100 inhibitory molecule (antimiR-100) or with the respective control molecules (premiR-ctrl or antimiR-ctrl, respectively) using Lipofectamine RNAiMAX. 24 h later, the luciferase reporter activity was measured according to the manufacturer protocol and finally, Firefly-luciferase activity was normalized to Renilla-luciferase activity.

Microarray analysis

A detailed methodology and complete raw data level of the array results were deposited at the Gene Expression Omnibus Database as described under the “Availability of data and materials” section. Briefly, total RNA from liver of C57BL/6J WT and global miR-100 overexpressing mice was isolated using TriPure (Roche Diagnostics) according to manufacturer’s protocol. Gene expression profiles of four independent samples for each condition were assessed using a MoGene-2_0-ST Array (ThermoFisher). We used Partek Genomics Suite software for further analysis (Partek, Inc.). Here, CEL files were imported including control and interrogating probes. Pre-background adjustment was set to adjust for GC Content and probe sequence and RMA background correction was performed. Arrays were normalized using quantile normalization and probe set summarization was done using median polish. Probe values were log2 transformed. In order to identify differentially expressed genes between the groups, we performed ANOVA in Partek.

MicroRNA and mRNA expression analysis

MiRNA expression was measured as described before (Pankratz et al. 2018) using quantitative taqman-based stem-loop PCR technology (TaqMan MiRNA Assay, Life technologies). The expression was normalized to the expression of the small RNA rnu19. A list of used assays is shown in Additional file 1: Table S3.

For quantitative real-time mRNA expression analysis, 1 µg of total RNA was transcribed using iScript Supermix (iScript, BioRad) according to manufacturer’s instructions as described before (Pankratz et al. 2018) and real-time PCR was performed on a MyiQ cycler (BioRad). The expression of mRNA was normalized to mouse 36B4.

For primer sequences please refer to Additional file 1: Table S4.

Western blot

Liver tissue was lysed in RIPA buffer and protein concentration was determined by Bradford assay (BioRad) following manufacturer's instructions. Total protein (30 µg per lane) was separated in 9% polyacrylamide-BisTris gels, transferred to PVDF membranes (Bio-Rad), and probed with specific primary antibodies overnight at 4 °C. After that, membranes were incubated with corresponding secondary antibodies for 2 h at room temperature and signals were detected by chemiluminescence using WesternBright reagents (Biozym) in a ChemiDoc MP imaging system (Bio-Rad). The intensity of the bands was analyzed using Image Lab software (Bio-Rad, Version 4.0 build 16). A list of antibodies used is presented in Additional file 1: Table S5.

Statistical analysis

Data are represented as mean values with SEM. Comparing two groups, significance was calculated by unpaired Student $t$-test with Prism 5 for Windows (GraphPad Software Inc, San Diego, CA, USA). When Gaussian distribution of our data could not be statistically verified, additional non-parametric testing was performed with Mann–Whitney U-tests. One-way ANOVA was used for multiple comparisons of >2 groups. The Bonferroni post-test for multiple comparisons was used if the P-value for the overall ANOVA comparison was statistically significant. Values of P < 0.05 were considered as statistically significant.

Results

Generation of a conditional miR-100 overexpressing transgenic mouse line

To investigate the function of miR-100 in liver metabolism, we developed a conditional miR-100 transgenic mouse line for a gain-of function approach together with a specialized service provider (Genoway, Lyon, France). We chose a conditional approach with expression of a 635 bp sequence coding for miR-100 and stabilizing flanking regions under the control of the CMV early enhancer/chicken beta actin (CCAG) promoter, followed by a loxp-stop-loxp cassette to enable a cell specific expression of miR-100 after breeding with a Cre-deleter strain. The conditional expression using a loxp-stop-loxp setup enabled both the ubiquitous miR-100 overexpression as well as the selective overexpression of miR-100 in specific cell populations. For this study, we decided for a breeding scheme with a CMV-Cre deleter strain (Fig. 1a) to investigate the effects of a ubiquitous miR-100 overexpression on metabolic function. The resulting breeding
colony was fertile and showed no phenotypic abnormalities. We could validate the functionality of our construct and found a 22-fold overexpression of miR-100 in liver tissue (Fig. 1b) of transgenic mice compared to wildtype controls.

Global gene expression analysis in liver tissue of transgenic miR-100 overexpressing mice

Next, we aimed to identify new direct and indirect metabolic target genes regulated by miR-100. Global transcriptome analysis was performed in liver samples of 6-months old transgenic miR-100 mice and wildtype animals as corresponding control. Statistic filtering and testing revealed a list of top nine downregulated genes in miR-100 global overexpressing mice, among them two genes, which are known to be strongly implicated in liver metabolism: fatty acid translocase /cluster of differentiation 36 (CD36) and cytochrome P450 4A14 (Cyp4a14) (Table 1) We could verify the downregulation of CD36 and Cyp4a14 in liver tissue of transgenic miR-100 mice on mRNA expression level (Fig. 1c, d).

Transgenic miR-100 mice show no metabolism-specific phenotypic or genotypic differences compared to wildtype controls under normal chow diet

Based on the results of the global transcriptome analysis, we investigated potential metabolic-specific phenotypic and genotypic changes in the transgenic, global miR-100 overexpressing mouse line under normal chow diet (ND) in a physiological setting. Body weight did not differ between the groups over a feeding period of 16 weeks under ND (Fig. 1e, f). Accordingly, we could not find any significant difference in food intake (determined in metabolic cages over 48 h, Fig. 1g). Additionally, the level of serum aspartate transaminase (AST) and alanine transaminase (ALT) of transgenic miR-100 mice were comparable to wildtype controls, suggesting no effect of miR-100 overexpression on normal liver function under physiologic condition (Fig. 1h, i, respectively). Next, we analyzed the whole body composition and could not find any differences in liver mass and fat deposition (Fig. 2a–d), overall indicating no significant impact of miR-100 on metabolic processes without an additional stressor. This conclusion was confirmed when we measured the expression of the key genes of fatty acid metabolism such as ACC1, FABP4, FAS and PPARγ (Fig. 2e–h). None of these parameters showed a significant regulation after miR-100 overexpression. Finally, we performed glucose and insulin tolerance tests in mice 18–19 weeks of age fed with normal chow diet and again, found no significant changes if miR-100 was globally overexpressed (Fig. 2i–l).

Table 1 Top downregulated genes in liver of miR-100 overexpressing mice

| Gene symbol | Name                                           | Fold change | P value |
|-------------|------------------------------------------------|-------------|---------|
| Cyp2b9      | Cytochrome P450, family 2, subfamily b, polypeptide 9 | -10.38      | 0.0008  |
| Cyp4a14     | Cytochrome P450, family 4, subfamily a, polypeptide 14 | -4.67       | 0.045   |
| Rps13-ps1   | Ribosomal protein S13, pseudogene 1             | -3.34       | 0.014   |
| Gdpd3       | Glycerophosphodiester phosphodiesterase domain containing 3 | -2.59       | 0.026   |
| Vnn1        | Vanin 1                                         | -2.30       | 0.044   |
| Cd36        | CD36 antigen                                     | -2.12       | 0.011   |
| LOC102643284| Adenosylhomocysteinase-like                     | -2.10       | 0.016   |
| Traj43      | T cell receptor alpha joining 43                | -2.05       | 0.009   |
| Cyp17a1     | Cytochrome P450, family 17, subfamily a, polypeptide 1 | -2.02       | 0.028   |

MiR-100 overexpression attenuates HFD-induced obesity and liver steatosis in mice

We next investigated the impact of this miRNA under pathophysiological condition by adding a high fat diet (HFD) as a metabolic stressor. A cohort of 2–3 weeks old male wildtype and transgenic miR-100 mice was fed ad libitum over a period of 16 weeks using a diet containing 60% of energy gained from fat. Wildtype

(See figure on next page.)

**Fig. 2** No metabolic changes under normal chow diet (ND) in miR-100 mice. a–d There was no difference in the weight of liver (a), brown fat tissue (b), subcutaneous fat (c) and visceral fat (d) at the end of the 16 weeks ND feeding period (age 18–19 weeks) in miR-100 overexpressing mice in comparison to the wildtype controls. e–h The expression of lipogenic genes in the liver of miR-100 mice was not significantly altered as seen by quantitative real-time PCR analysis compared to WT animals. i–j The intraperitoneal glucose tolerance test at the end of the feeding period revealed no difference in WT and miR-100 mice. k, l The intraperitoneal insulin tolerance test at the end of the feeding period showed no change in miR-100 mice compared to wildtype controls. (n=5–6 for all experiments) Data represent mean values with SEM. n.s. not significant vs. the corresponding control.
Fig. 2 (See legend on previous page.)
mice under HFD showed a twofold enhanced miR-100 expression compared to ND wildtype controls (Fig. 3a) and also transgenic miR-100 mice under HFD exhibited a twofold upregulation of miR-100 when compared to transgenic mice fed with ND (Fig. 3b).

Although the food intake was comparable between transgenic mice and wildtype controls as determined by housing the mice in metabolic cages (48 h at beginning and at the end of the study, Fig. 3c), we observed a significantly reduced overall weight gain in transgenic miR-100 overexpressing mice (Fig. 3d, e). Analysis of the body composition revealed a significantly reduced liver mass as well as subcutaneous and visceral adipose tissue (Fig. 3f, h, i). The content of brown fat was unaffected (Fig. 3g).

Based on the observed difference in fat disposition, we next examined whether a global miR-100 overexpression affected cholesterol- and triglyceride homoeostasis. We did not find any significant changes in serum cholesterol, triglyceride and HDL (Fig. 3j–l), but levels of LDL cholesterol were decreased (Fig. 3m). However, whereas the cholesterol content in the transgenic liver samples was not affected, we observed a reduced content of triglycerides extracted from liver tissue of miR-100 overexpressing mice (Fig. 4a, b). Moreover, we could detect a significantly reduced serum AST in miR-100 mice, whereas ALT did not differ compared to WT animals (Fig. 4c, d). Additionally, we found less Oil Red O positive staining (Fig. 4e, f) and reduced fat accumulation as quantified by HE staining (Additional file 2: Fig. S1) in miR-100 mice, indicating an influence of this miRNA in the regulation of fatty acid storage in hepatocytes.

In good correspondence to the observed effects on body weight and liver steatosis, we found that transgenic miR-100 overexpressing mice displayed an improved GTT (Fig. 4g, h) as well as ITT (Fig. 4i, j) compared to wildtype animals under a HFD at the end of the feeding period, whereas no significant difference in GTT (Additional file 2: Fig. S2a, b, e, f) and ITT (Additional file 2: Fig. S2c, d, g, h) could be detected at the start of ND (Additional file 2: Fig. S2a–d) and HFD (Additional file 2: Fig. S2e–h).

**HFD mediated induction of fat metabolism is attenuated in miR-100 mice**

We went on to analyze the lipogenic gene profile in transgenic miR-100 and wildtype mice in the pathophysiological setting of a HFD. In contrast to our findings under ND, miR-100 overexpression under metabolic stress significantly reduced the expression of the key genes and proteins of fatty acid storage and -metabolism such as CD36, ACC1, FABP4, FAS and PPARY in liver tissue (Fig. 5a, b, d–i, k, l). Additionally, we also found a significant attenuation of Cyp4A14 expression in miR-100 overexpressing mice under HFD, which is in good correspondence to our finding in the initial screening experiment (Fig. 5c, j).

Interestingly, although CD36 is not listed as a potential direct miR-100 target in common target site prediction tools such as Targetscan (Friedman et al. 2009; Grimson et al. 2007; Lewis et al. 2005) and miRBase (Kozomara et al. 2019), we found potential binding sites for miR-100 in the 3’UTR of the mouse CD36 mRNA sequence (Fig. 6a). To confirm a direct regulation of CD36 by miR-100, a dual-luciferase reporter assay using the Luc-Pair™ Duo-Luciferase assay system was performed. Huh7 cells were co-transfected with both the plasmid containing the sequence of the CD36 3’UTR and premiR-100 or anti-miR-100 or their respective control plasmids. Indeed, our results showed a modulation of CD36 through miR-100 by interacting with the 3’UTR of CD36, for the first time validating CD36 as a direct miR-100 target (Fig. 6b, c).

**Fatty acid uptake is reduced in cultured miR-100 overexpressing primary hepatocytes**

Our findings of a direct regulation of CD36 by miR-100 in combination with lower triglyceride content in liver tissue of miR-100 transgenic mice subsequently resulted in the investigation of the fatty acid uptake capacity of hepatocytes either isolated from the transgenic global miR-100 mice or wildtype animals. Primary hepatocytes were treated with the fluorescently labelled oleic acid analogue BODIPY FL C16 and incorporation of this fatty acid in primary hepatocytes was monitored using fluorescence microscopy. We found a reduced uptake of BODIPY reagent in miR-100 overexpressing hepatocytes (Fig. 6d, e), supporting the hypothesis that miR-100...
Fig. 3 (See legend on previous page.)
impairs the uptake and in consequence the storage of fatty acids in the liver by regulating CD36.

**MiR-100 mice demonstrate increased energy expenditure**

Additionally to the expression analysis, we investigated the physical activity and energy expenditure (heat) of wildtype and miR-100 mice under ND and HFD conditions, using the comprehensive laboratory animal monitoring system (CLAMS). Surprisingly, we found that miR-100 overexpressing mice showed significantly less total ambulatory moving under ND and HFD during the day (Fig. 7a, i), which is in strong contrast to our finding that miR-100 mice develop less weight gain (Fig. 3d, e) but eat similar (Fig. 3c). The ambulatory moving in the dark (Fig. 7e, m) showed no significant difference. Possibly, the observed discrepancy between the decreased weight gain and less moving combined with comparable food intake in HFD fed miR-100 animals may be caused by an increased internal heat production. And indeed, indirect calorimetry analysis using the CLAMS system revealed that the heat production was significantly increased in HFD fed transgenic miR-100 mice compared to wildtype controls during both, day and night (Fig. 7j, n). Correspondingly, the total volume of oxygen consumed (VO2, Fig. 7k, o) and the carbon dioxide produced (VCO2, Fig. 7l, p) were significantly increased in our transgenic miR-100 mice under HFD feeding during day and night. Under ND conditions, there were no significant changes in heat production, O2 consumption or CO2 production between wildtype and miR-100 mice detectable (Fig. 7b–d during the day and Fig. 7f–h during the night).

**Reduced inflammation in the liver of HFD fed miR-100 mice**

Obesity is strongly associated with chronic inflammatory processes and when examining inflammation-related genes such as IL-1β as well as TNF-α we found a significantly attenuated expression in liver tissue of transgenic miR-100 mice that underwent a HFD for 16 weeks (Additional file 2: Fig. S3a, b). Additionally, the expression of the oxidative stress marker Vanin-1 was also reduced in the liver of miR-100 overexpressing mice under HFD conditions (Additional file 2: Fig. S3c).

**Discussion**

Disproportional nutrient intake and metabolic dysregulation can result in obesity and hepatic steatosis, which occurs in 10–25% of people worldwide and are major risk factors for the development metabolic and cardiovascular diseases (Wilson et al. 2016). In the current study, we describe a transgenic mouse strain with a ubiquitous overexpression of miR-100, which is partially protected against these harmful sequelae of a HFD. MiR-100 overexpressing mice gain less excessive weight and develop less visceral and subcutaneous fat tissue than wildtype animals. In addition, they exhibit a lower liver mass due to less fat accumulation, accompanied by less hepatic inflammation, an improved glucose tolerance and increased insulin sensitivity. The metabolic phenotype under a normal diet remains unaffected by miR-100.

Our findings support previous reports linking miR-100 to metabolic diseases: Pek et al. found miR-100 to be downregulated in blood and visceral fat of patients with obesity and type 2 diabetes (Pek et al. 2016) and showed that miR-100 inhibition results in an increased adipocyte differentiation whereas an inhibition of miR-100 reduces the differentiation potential of 3T3-L1 cells. In addition, Ortega et al. showed that miR-100 expression decreased during adipocyte differentiation. The known regulation of mTOR-signaling by miR-100 was presumed to be the responsible mechanism (Ortega et al. 2010).

In contrast to our findings of protective effects of miR-100 overexpression on liver steatosis, most other studies address the inhibition of liver specific miRNAs. Anti-sense treatment against miR-122 as the most abundant miRNA in the liver, has been shown to prevent hepatic steatosis (Esau et al. 2006) and loss of miR-22 reduced fat mass gain and prevented HFD induced dyslipidemia by diminishing the expression of genes involved in lipogenesis (Diniz et al. 2017). A protective role of miR-155 in non-alcoholic hepatosteatosis was described by Miller et al., who found an increased hepatic steatosis in miR-155 knockout animals under HFD, associated with increased liver weight and serum VLDL/LDL level (Miller et al. 2013). Our study now adds miR-100 as...
Fig. 4 (See legend on previous page.)
another potential protective “metabomiR” to this study field. Besides the possible regulatory function of miRNAs in NAFLD, another aspect could be the use as biomarker to diagnose the different stages of NAFLD as liver biopsy is to date the gold standard diagnosis method. Specifically, miR-122 and miR-34a serum level have been shown to correlate with among others hepatic inflammation and fibrosis stage (Cermelli et al. 2011; Jampoka et al. 2018; Liu et al. 2018a). However, miR-100 is not exclusively expressed in liver tissue and whether this microRNA is differentially expressed in serum of patients suffering from NAFLD needs to be further elucidated.

In our current study, global gene expression analysis in hepatic tissue from miR-100 overexpressing and wildtype mice fed with ND reveals two other genes involved in lipid metabolism and storage among the top 9 downregulated genes: the scavenger receptor and fatty acid transporter CD36 (CD36) and the cytochrome P450 omega-hydroxylase 4A14 (Cyp4a14). CD36 belongs to the class B of the scavenger receptor family and is able to bind a variety of molecules, including oxidized LDL, phospholipids, collagen and long chain fatty acids (Endemann et al. 1993; Febrero et al. 2002; Liu et al. 2018b). It is highly expressed in cardiomyocytes, skeletal muscle cells, adipocytes and macrophages (Ibrahim et al. 1999) and at markedly lower levels in hepatocytes, but hepatic expression increases rapidly under lipid rich diets, hepatic steatosis and in nonalcoholic fatty liver disease (NAFLD) (Greco et al. 2008; Miquilena-Colina et al. 2011). Increased CD36 expression has been shown to correlate with dyslipidemia (Koonen et al. 2007) and inflammatory hepatic stress (Liu et al. 2018b) as well as to enhance the susceptibility to develop hepatic steatosis and NAFLD (Sheedfar et al. 2014; Steneberg et al. 2015).

In rodents, the hepatocyte specific disruption of CD36 attenuates the development of fatty liver diseases and insulin resistance induced by a HFD (Bonen et al. 2015; Rodrigue-Way et al. 2014), has been shown to be repressed by downregulation of CD36 (Demers et al. 2008; Rodrigue-Way et al. 2014), and to be increased in HFD-induced nonalcoholic fatty liver disease (Zhang et al. 2006). Inhibition of Cyp4A14 results in the attenuation of insulin resistance and apoptosis in diabetic mice (Park et al. 2014) and Zhang et al. found a reduced hepatic lipid accumulation accompanied with a diminished expression of liver Fat/CD36 expression (Zhang et al. 2017) which is in good correspondence to our findings in the transgenic miR-100 mouse strain.

Despite pronounced effects of miR-100 on its direct target mTOR in cardiovascular cells as shown by our group (Pankratz et al. 2018), these metabolic key enzyme seems to play a minor role as a miR-100 target in hepatic cells as our screening experiment does not reveal a diminished expression of liver Fat/CD36 expression (Zhang et al. 2017) which is in good correspondence to our findings in the transgenic miR-100 mouse strain. Interestingly, while the changes in metabolic gene expression are already detectable under normal diet, the changes in the metabolic phenotype of miR-100 overexpressing mice are only observed under HFD, arguing for the dependency of miR-100 mediated effects on this metabolic stressor. In addition to the observed effects on the direct miR-100 targets described above, miR-100 overexpressing mice show a downregulation of several additional key mediators of fatty acid storage and metabolism. Especially the expression of the master regulator of adipogenesis PPARγ (Lefterova et al. 2014) is markedly decreased, along with the reduction of its downstream target genes ACC1, FABP4 and FAS, potentially contributing to the observed effects on lipogenesis and fatty acid uptake. Although the precise regulation of these metabolic mediators is not investigated in our study, PPARγ has been shown to be repressed by downregulation of CD36 (Demers et al. 2008; Rodrigue-Way et al. 2014), which is in good correspondence with our findings.

As an interesting detail, metabolic cage phenotyping of our transgenic mice shows that the difference in weight gain is independent of nutrient intake and movement. Indeed, miR-100 overexpressing mice gain less weight despite a more sedentary behavior with less ambulatory movement, but a higher oxygen consumption, which can be caused by an uncoupling.
Fig. 5 (See legend on previous page.)
MiR-100 overexpression attenuates lipid accumulation in primary cultured hepatocytes. a The illustration shows the potential binding site of miR-100 in the 3′ UTR of CD36. b The luciferase activity was reduced when the CD36 3′ UTR plasmid and miR-100 precursor molecules (premiR-100) were overexpressed (n = 8). c The luciferase activity was induced when the CD36 3′ UTR plasmid was overexpressed together with the miR-100 inhibitory molecule antimiR-100 (n = 8). d Exemplary fluorescence images of BODIPY FL C16 uptake in primary cultured mouse hepatocytes isolated from wildtype and miR-100 overexpressing mice are shown (Magnification: ×400). The hepatocytes were treated with DMSO control or BODIPY FL C16 at 200 nM for 1 h. e The quantification of BODIPY FL C16 revealed a reduced uptake into hepatocytes isolated from miR-100 overexpressing mice. (n = 6–7) Data represent mean values with SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the corresponding control.

MiR-100 mice demonstrate increased energy expenditure under high fat diet but not normal chow diet. a–h At the end of the ND feeding period, the comprehensive laboratory animal monitoring system (CLAMS) measured ambulatory moving (a, e), heat generation (b, f), O2 consumption (c, g) and CO2 production (d, h). The graphs indicate the average during the day (a–d) and night (e–h). i–p At the end of the HFD feeding period, the CLAMS measured ambulatory moving (i, m), heat generation (j, n), O2 consumption (k, o) and CO2 production (l, p). The graphs indicate the average during the day (i–l) and night (m–p). (ND n = 5–6 and HFD n = 13) Data represent mean values with SEM. n.s. not significant, *P < 0.05 and ***P < 0.001 vs. the corresponding control.
Fig. 7 (See legend on previous page.)
from oxidative phosphorylation in other tissues in transgenic miR-100 mice or by a minor contribution of the locomotor activity to the total energy expenditure compared to the basal metabolism. However, further investigation has to be performed to clarify the coherences.

The observed effects of diminished serum triglycerides of our transgenic miR-100 mice following HFD in the current study fits very well to our other findings on miR-100 dependent effects on different aspects of metabolic syndrome, but it is in partial contrast to our previous study linking miR-100 to chronic vascular inflammation (Pankratz et al. 2018). Here, we observed an overall reduction of serum triglycerides and cholesterol following pharmacological overexpression of miR-100 under high cholesterol diet. However, both studies differ in regard to diet (high fat vs. high cholesterol diet), feeding time (8 vs. 16 weeks), overexpression approach (transgenic vs. pharmacological) and genetic background (C57BL/6J and LDLR-/−).

It has to be noticed that serum cholesterol and triglycerides were determined under non-fasting conditions, nevertheless, it has been shown that many metabolites are not drastically affected by fasting status (Langsted and Nordestgaard 2019; Stevens et al. 2019).

Conclusions
In summary, we add miR-100 as a novel “metabomiR” with a protective function in metabolic syndrome by reducing weight gain, liver steatosis and hypertriglyceridermia. In detail, miR-100 reduces the expression of lipogenic enzymes and directly interacts with CD36, preventing excessive lipid accumulation in the liver. Interestingly, transgenic miR-100 mice display less weight gain despite concurrent reduced ambulatory movement. Further studies addressing the underlying effects of this observation are warranted and could offer new insights into the pathogenesis of metabolic syndrome and possible miRNA-based therapeutic strategies.

Abbreviations
36B4: Acidic ribosomal phosphoprotein P0; 3′UTR: Three prime untranslated region; ACC1: Acetyl-CoA carboxylase; antimiR: MicroRNA inhibitor molecule; BMI: Body mass index; CD36: Fatty acid translocase; CMV: Cytomegalovirus; GAPDH: Glucose-6-phosphate dehydrogenase; GPT: Glutamate-pyruvate transaminase; GPP: Glutamate-pyruvate transaminase; HFD: High fat diet; HE: Hematoxylin and eosin stained sections; HFF: Human foreskin fibroblasts; HNF: Hepatic nuclear factor; IL-1β: Interleukin 1 beta; IL-6: Interleukin 6; ITT: Insulin tolerance test; LDL: Low-density lipoprotein; miR: MicroRNA; NAFLD: Nonalcoholic fatty liver disease; N2: Dinitrogen; ND: Normal chow diet; O2: Dioxygen; PBS: Phosphate buffered saline; PCR: Polymerase chain reaction; PPARα: Peroxisome proliferator-activated receptor alpha; PPARγ: Peroxisome proliferator-activated receptor gamma; pre-miR: Precursor microRNA; Product ID: Product identification; Pr: A: Ras-related protein Ras-A; RNA: Ribonucleic acid; VLDL: Very-low-density lipoprotein; WT: Wildtype.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s10020-021-00364-6.

Additional file 1: Table S1. Normal chow diet (ND) composition. The ND (ND#3437) was purchased from Liba NAFAG, Kaiseraugst, Switzerland.
Table S2. High fat diet (HFD) composition. The HFD (sniff EF acc. D12492 mod.) was purchased from sniff Specialdiäten GmbH, Soest, Germany.
Table S3. List of Taqman assays used for quantitative stem-loop PCR analysis and miRNA molecules used for transfection. Table S4. List of primer sets used for SYBR green based quantitative real-time PCR analysis.
Table S5. List of primary and secondary antibodies used for Western blot analysis.

Additional file 2: Figure S1. Fat accumulation under high fat diet is reduced in miR-100 mice compared to wildtype. (a) Representative pictures of paraffin preserved liver sections (8 µm) stained for HE are shown. (b) The quantification of fat accumulation (white areas) was done using Image J software. (n = 13–14) Data represent mean values with SEM. ***P < 0.001 vs. the corresponding control. Figure S2. No changed glucose tolerance and insulin sensitivity in miR-100 mice at start of the 16 weeks normal chow and high fat diet feeding period. (a−d) MiR-100 mice showed no altered glucose tolerance in the GTT (a,b) and insulin sensitivity in the ITT (c,d) compared to wildtype animals fed normal chow diet before the feeding period started (age 2–3 weeks, n = 5–6). (e−h) MiR-100 mice showed no altered glucose tolerance in the GTT (e,f) and insulin sensitivity in the ITT (g,h) compared to wildtype animals before the high fat feeding period started. (age 2–3 weeks, n = 13–14) Data represent mean values with SEM. n.s. = not significant, **P < 0.05, ***P < 0.01 and ****P < 0.001 vs. the corresponding control. Figure S3. Reduced inflammation in the liver of mice under high fat diet feeding. (a,b) Quantitative real-time PCR analysis at the end of the HFD feeding period revealed a significant reduction of the inflammatory marker genes IL-1β and TNFα in miR-100 livers. (c) The expression of the oxidative stress marker Vnn1 is also significantly reduced in the liver of mice under high fat diet feeding. (a,b) Quantitative real-time PCR analysis at the end of the HFD feeding period revealed a significant reduction of the inflammatory marker genes IL-1β and TNFα in miR-100 livers.

Figure S2. No changed glucose tolerance and insulin sensitivity in miR-100 mice at start of the 16 weeks normal chow and high fat diet feeding period. (a−d) MiR-100 mice showed no altered glucose tolerance in the GTT (a,b) and insulin sensitivity in the ITT (c,d) compared to wildtype animals fed normal chow diet before the feeding period started (age 2–3 weeks, n = 5–6). (e−h) MiR-100 mice showed no altered glucose tolerance in the GTT (e,f) and insulin sensitivity in the ITT (g,h) compared to wildtype animals before the high fat feeding period started. (age 2–3 weeks, n = 13–14) Data represent mean values with SEM. **P < 0.01 and ***P < 0.001 vs. the corresponding control.

Acknowledgements
We thank the Core Facility Signalling Factory of the University Freiburg for material supply.

Authors’ contributions
CS designed research; CS and DP performed research; DS, CH, XB, CJ, LS, JM, DP, MM, PH and CB contributed to the research; CS and DP analyzed data; and CS, DS, SG and FP wrote the paper. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This study is supported by the Else-Kröner-Fresenius Stiftung, Germany to FP (2016_ A106). The funding did not have any influence on study design and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets supporting the conclusion of this article are included within the article and Additional files 1 and 2. Microarray data are available in Gene Expression Omnibus Database at https://www.ncbi.nlm.nih.gov/geo/; and can be accessed with Accession Number GSE167603.
Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2 Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3 Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Received: 15 June 2021 Accepted: 25 August 2021
Published online: 06 September 2021

References

Almeida DL, et al. Early postnatal overnutrition impairs VO2max gains with moderate exercise and increase post-exercise muscle damage in adult male rats. J Dev Orig Health Dis. 2021. https://doi.org/10.1007/s12944-021-00428-x.

Arner P, Kulyte A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol. 2015;11:276–88. https://doi.org/10.1038/nrendo.2015.25.

Bonen A, et al. Extremely rapid increase in fatty acid transport and intramyocellular lipid accumulation but markedly delayed insulin resistance after high fat feeding in rats. Diabetologia. 2015;58:2381–91. https://doi.org/10.1007/s00125-015-3961-8.

Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE. 2011;6:e23937. https://doi.org/10.1371/journal.pone.0023937.

Chartoumpekis DV, Zaravinos A, Ziros PG, Iskrenova RP, Psyrogiannis AI, Kyriazopoulou VE, Habeos IG. Differential expression of microRNAs in adipose tissue of patients with chronic hepatitis and non-alcoholic fatty liver disease. J Cell. 2007;28:99–108. https://doi.org/10.1016/j.mc2.2006.11.005.

Esau C, et al. MiR-122 regulation of lipid metabolism revealed by in vivo antiinsulin targeting. Cell Metab. 2006;3:87–98. https://doi.org/10.1016/j.cmet.2006.01.005.

Febbraio M, Guy E, Coburn C, Knapp FF Jr, Beets AL, Abumrad NA, Silverstein RL. The impact of overexpression and deficiency of fatty acid translocase (FAT)/CD36 on obesity. Mol Cell Biochem. 2002;239:193–7.

Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–103. https://doi.org/10.1101/gr.082701.108.

Gerin J, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem. 2010;285:33652–61. https://doi.org/10.1074/jbc.M110.152090.

Greco D, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1281-1287. https://doi.org/10.1152/ajpgi.00074.2008.

Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91–105. https://doi.org/10.1016/j.molcel.2007.06.017.

Heneghan HM, Miller N, McNeney OJ, O’Brien T, Kerin MJ. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011;96:648-650. https://doi.org/10.1210/jc.2010-2070.

Horie T, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA. 2010;107:1732–6. https://doi.org/10.1073/pnas.1008499107.

Iacomino G, Siani A. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 2017;12:23. https://doi.org/10.1186/s11162-017-0577-z.

Ibrahim A, et al. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem. 1999;274:27661–6. https://doi.org/10.1074/jbc.274.38.27661.

Jampoka K, Muangpaisarn P, Khongninman T, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). Microrna. 2018;7:215–22. https://doi.org/10.2174/221536607051933020.

Kiran S, Kumar V, Kumar S, Price RL, Singh UP. Adipocyte, immune cells, and miRNA crosstalk: a novel regulator of metabolic dysfunction and obesity. Cells. 2021. https://doi.org/10.3390/cells10051004.

Koonen DP, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;56:2863–71. https://doi.org/10.2337/db07-0907.

Kozomara A, Birgaounau M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47:D155–62. https://doi.org/10.1093/nar/gky1141.

Langsted A, Nordestgaard BG. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019;51:131–41. https://doi.org/10.1016/j.pathol.2018.09.062.

Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. Ppargamma and the Global Map of Adipogenesis and beyond Trends Endocrinol Metab. 2014;25:293–302. https://doi.org/10.1016/j.tem.2014.04.001.

Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20. https://doi.org/10.1016/j.cell.2004.12.035.

Li K, Zhao B, Wei D, Wang W, Cui Y, Qian L, Liu G. miR146a improves hepatic lipid and glucose metabolism by targeting MED1. Int J Mol Med. 2020;45:543–55. https://doi.org/10.3892/imm.2019.9443.

Liu CH, et al. miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2018a;69:1335–48. https://doi.org/10.1016/j.jhep.2018.08.008.

Liu J, et al. Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress. Lipids Health Dis. 2018b;17:153. https://doi.org/10.1186/s12944-018-0790-9.

Marquart TJ, Allen RM, Ory DS, Baldwin A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA. 2010;107:12228–32. https://doi.org/10.1073/pnas.1005191107.

Martellini R, et al. miR-319d overexpression is associated with human obesity. Obesity (Silver Spring). 2010;18:2170–6. https://doi.org/10.1038/oby.2009.474.

Mikusova V, Mikus J, Grilusova K, Roncakova M, Benko J, Martinka E. Insulin resistance and need for a lifestyle change to eliminate it. Bratisl Lek Listy. 2021;122:567–71. https://doi.org/10.4149/BLL_2021_090.

Miller AM, et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE. 2013;8:e72334. https://doi.org/10.1371/journal.pone.0072334.

Muñoz-Pinedo C, et al. Hepatic fatty acid translocate CD36 upregulation is associated with insulin resistance, hyperinsulinemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011;60:1394–402. https://doi.org/10.1136/gut.2010.228844.

Najafi-Shourabi SR, Khosravi F, Li Y, Shioda T, Cohen DE, Genszen RE, Naar AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328:1566–9. https://doi.org/10.1126/science.1189123.
Ortega FJ, et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS ONE. 2010;5: e9022. https://doi.org/10.1371/journal.pone.0009022.

Pankratz F, et al. MicroRNA-100 suppresses chronic vascular inflammation by stimulation of endothelial autophagy. Circ Res. 2018;122:417–32. https://doi.org/10.1161/CIRCRESAHA.117.311428.

Park EC, et al. Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice. Gastroenterology. 2014;147:860–9. https://doi.org/10.1053/j.gastro.2014.06.039.

Patsouris D, Reddy JK, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology. 2006;147:1508–16. https://doi.org/10.1210/en.2005-1132.

Pek SL, Sum CF, Lin MX, Cheng AK, Wong MT, Lim SC, Tavintharan S. Circulating and visceral adipose miR-100 is down-regulated in patients with obesity and type 2 diabetes. Mol Cell Endocrinol. 2016;427:112–23. https://doi.org/10.1016/j.mce.2016.03.010.

Rivera-Gonzalez O, Wilson NA, Coats LE, Taylor EB, Speed JS. Endothelin receptor antagonism improves glucose handling, dyslipidemia, and adipose tissue inflammation in obese mice. Clin Sci (Lond). 2021. https://doi.org/10.1042/CS20210549.

Rodrique-Way A, et al. Scavenger receptor CD36 mediates inhibition of cholesterol synthesis via activation of the PPARgamma/PGC-1alpha pathway and Insig1/2 expression in hepatocytes. FASEB J. 2014;28:1910–23. https://doi.org/10.1096/fj.13-240168.

Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239–50. https://doi.org/10.1038/nrm3313.

Sheedfar F, et al. Increased hepatic CYP4A expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease. Aging (Albany NY). 2014;6:281–95. https://doi.org/10.18632/aging.100652.

Singh AK, et al. Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice. J Clin Invest. 2021. https://doi.org/10.1172/JCI109889.

Steneberg P, Sykaras AG, Backlund F, Straseviene J, Soderstrom L, Edlund H. Hyperinsulinemia enhances hepatic expression of the fatty acid transporter Cd36 and provokes hepatosteatosis and hepatic insulin resistance. J Biol Chem. 2015;290:19034–43. https://doi.org/10.1074/jbc.M115.640292.

Stevens VL, Hoover E, Wang Y, Zanetti KA. Pre-analytical factors that affect metabolite stability in human urine, and serum: a review. Metabolites. 2019. https://doi.org/10.3390/metabo9080156.

Vural Keskinler M, Feyzoglu G, Yildiz K, Oguz A. The frequency of malnutrition in patients with type 2 diabetes. Medeni Med J. 2021;36:117–22. https://doi.org/10.5114/mmj.2021.44270.

Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M, Weiss EJ. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology. 2016;157:570–85. https://doi.org/10.1210/en.2015-1518.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.